Single Dose of Furosemide to Improve Respiratory Distress in Moderate to Severe Bronchiolitis

Model scores of the 29,894 trials active now.

Model score 15% for any early termination, 6% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 13% of the time (331 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2016-04-30. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Sponsor's past termination rate: 31.9% (raises risk) · Sponsor's track record
• Accepts healthy volunteers: No (raises risk) · Who can join
• Wording of the registration (title, summary, criteria) (lowers risk) · Wording Phrases that raised it: patientacutedialysistherapydefined by
  Phrases that lowered it: moderaterespiratoryto severesingle dosemild
• Phase: 2 (raises risk) · Design
• Blinding: quadruple (lowers risk) · Design
• Has a data monitoring committee: Yes (raises risk) · Design
• Disease area, cancer: No (lowers risk) · Disease area
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Drug's FAERS reports before start: 93670 (lowers risk) · Drug's FDA history
• Design: parallel (raises risk) · Design
• Drug's FAERS reports with a death: 18.8% (lowers risk) · Drug's FDA history
• Maximum age: 4 (raises risk) · Who can join
• Primary purpose: treatment (raises risk) · Design
• Drug's FAERS reports in the prior 12 months: 12195 (lowers risk) · Drug's FDA history
• Disease area, neurology: No (lowers risk) · Disease area
• Minimum age: not given (raises risk) · Who can join
• Number of arms: 2 (raises risk) · Design
• Responsible party: principal investigator (lowers risk) · Design
• Sponsor's past trials: 47 (lowers risk) · Sponsor's track record
• Disease area, respiratory: Yes (raises risk) · Disease area
• Trials the sponsor started in the prior 2 years: 16 (lowers risk) · Sponsor's track record
• Keywords listed: 0 (lowers risk) · Design
• Collaborators: 0 (raises risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Moderate to Severe Bronchiolitis: Standard Therapy Versus Therapy With NaCl 3% Inhalations NCT01812525 · started 2013 · scored riskier than 21% of active trials completed
• Dexamethasone in the Treatment of Bronchiolitis in Patients With Either Eczema and or Family History of Asthma NCT01065272 · started 2010 · scored riskier than 21% of active trials completed
• High Flow Therapy vs Hypertonic Saline in Bronchiolitis NCT01873144 · started 2010 · scored riskier than 39% of active trials completed
• The Effectiveness of Nebulized Hypertonic Saline Solution for Acute Bronchiolitis NCT02760719 · started 2015 · scored riskier than 11% of active trials terminated
• Nebulized Adrenalin and Oral Betamethasone in Children With Bronchiolitis Attending Pediatric Emergencies. NCT02586961 · started 2015 · scored riskier than 34% of active trials terminated

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.